Lucid Diagnostics Inc - Asset Resilience Ratio
Lucid Diagnostics Inc (LUCD) has an Asset Resilience Ratio of 6.09% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Lucid Diagnostics Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2022)
This chart shows how Lucid Diagnostics Inc's Asset Resilience Ratio has changed over time. See LUCD total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Lucid Diagnostics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Lucid Diagnostics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.59 Million | 6.09% |
| Total Liquid Assets | $2.59 Million | 6.09% |
Asset Resilience Insights
- Limited Liquidity: Lucid Diagnostics Inc maintains only 6.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lucid Diagnostics Inc Industry Peers by Asset Resilience Ratio
Compare Lucid Diagnostics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for Lucid Diagnostics Inc (2019–2022)
The table below shows the annual Asset Resilience Ratio data for Lucid Diagnostics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 4.09% | $1.33 Million | $32.51 Million | +2.20pp |
| 2021-12-31 | 1.89% | $1.12 Million | $59.00 Million | -3.48pp |
| 2020-12-31 | 5.38% | $118.00K | $2.19 Million | -6.05pp |
| 2019-12-31 | 11.42% | $118.09K | $1.03 Million | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the… Read more